Boston Scientific Corporation (NYSE:BSX) reported net sales of approximately $4.6 billion in the fourth quarter of 2024, a 22.4% increase from the same period last year.

Boston Scientific Corporation BSX remains in the spotlight, with its stock currently trading close to its 52-week high. In the past six trading sessions, the stock has consistently traded above ...

Boston Scientific (NYSE: BSX) has more than doubled in value since early January 2021 – jumping from levels of $36 then to around $82 now – vs. an increase of about 45% for the S&P 500 over ...

Boston Scientific closed up more than 4% on Apr. 22 after releasing its Q1 earnings. It boosted its full-year net sales forecast to 15% to 17% from a prior view of 12.5% to 14.5%.

Needham downgraded Boston Scientific (NYSE:BSX) to Hold from Buy on Friday, noting a potential stagnation in its topline growth next year due to a slowdown in the company's electrophysiology business.

The average brokerage recommendation (ABR) for Boston Scientific (BSX) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly ...